Effect of vasoactive intestinal peptide (VIP) on the release of adenohypophyseal hormones from purified cells obtained by unit gravity sedimentation

Rotsztejn, W.H.; Benoist, L.; Besson, J.; Beraud, G.; Bluet-Pajot, Marie Thérèse; Kordon, C.; Rosselin, G; Duval, Jacques

doi:10.1016/0167-0115(80)90206-2

Cited by 21 publications

(27 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…How ever, VIP has been shown to stimulate the release of GH and LH in vivo [21]. Our observations are in agreement with the fact that VIP can stimulate PRL release by acting at the pituitary level as previously reported [16]. Likewise, the ab sence of the immunochemical reaction in the gonadotropic and somatotropic cells is in good agreement with the hy pothesis that VIP stimulates LH and GH release at the hy pothalamic level [21].…”

Section: Discussionsupporting

confidence: 81%

“…VIP is known to increase the PRL release in vitro, but it does not affect the LH, FSH or ACTH release [16]. How ever, VIP has been shown to stimulate the release of GH and LH in vivo [21].…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, adenohypophyseal hormone release is stimulated by the in traventricular injection of VIP [10,21], Direct effects of VIP on prolactin secretion were evidenced in prolactin-secreting cells; doses as low as I0~9M induced a rise in cycIic-AMP and a release of prolactin [9]. Production of prolactin (PRL) by physiological doses of VIP was also observed in enriched preparations of normal PRL-secreting cells [16]. In order to investigate (1) whether VIP is present in the pituitary gland, and (2) to localize VIP at the cellular and subcellular levels, the immunocytological method was performed on ultrathin sections of anterior pituitary glands.…”

mentioning

confidence: 94%

See 2 more Smart Citations

Ultrastructural Evidence for Endogenous Vasoactive Intestinal Peptide-Like Immunoreactivity in the Pituitary Gland

Morel¹,

Besson

Rosselin

et al. 1982

Neuroendocrinology

Self Cite

View full text Add to dashboard Cite

The immunocytological method was used to investigate whether vasoactive intestinal peptide (VIP) is present in the pituitary gland and to localize the peptide at the cellular and subcellular levels. Pituitaries of Wistar male and female rats (Iffa Credo) were fixed in glutaraldehyde 2.5% and postosmicated and frozen in liquid nitrogen. Ultrathin slices, obtained by cryo-ultramicrotomy were incubated with the antiserum. The antigen-antibody reaction was detected by peroxidase-antiperoxidase complexes revealed by 4-chloro-1-naphtol. The prolactin (PRL)-secreting cells were identified by using an anti-oPRL antiserum. The PRL immunoreactivity was localized in secretory granules of irregular shapes. An anti-VIP serum was used which neither cross-reacted with the several fragments of VIP molecule nor with peptides from gut or hypothalamus. The VIP immunoreactivity obtained with this antiserum, was observed in PRL cells only but never in somatotropic, gonadotropic, corticotropic and thyrotropic cells. The immunoreactivity was localized in the cytoplasmic matrix between and around the secretory granules but not in the organelles, and in the nucleus distributed all over the euchromatin near to the heterochromatin regions. No reaction was observed by using either nonimmune serum or anti-VIP antiserum incubated with VIP. No modification of VIP immunoreactivity was observed by using anti-VIP antiserum incubated with somatostatin, gonado- or thyroliberin. These data (1) provide immunocytological evidence for presence of VIP in pituitary gland; (2) indicate the presence of this peptide in one particular pituitary cell type, and (3) support the hypothesis that VIP could have a direct effect on the control of PRL secretion.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 94%

See 1 more Smart Citation

Ultrastructural Evidence for Endogenous Vasoactive Intestinal Peptide-Like Immunoreactivity in the Pituitary Gland

Morel¹,

Besson

Rosselin

et al. 1982

Neuroendocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This extends our previous observations demonstrating the presence of VIP receptors on purified rat PRL cells (23). Those data together with the specific stimulatory effect of VIP on PRL release (6) give further support to the hypothesis that VIP acts as a PRLreleasing factor on the pituitary.…”

Section: Discussionsupporting

confidence: 78%

Rapid glucocorticoid inhibition of vasoactive intestinal peptide-induced cyclic AMP accumulation and prolactin release in rat pituitary cells in culture.

Rotsztejn¹,

Dussaillant²,

Nobou³

et al. 1981

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Vasoactive intestinal peptide (VIP) stimulates both adenosine 3',5'-cyclic monophosphate (cAMP) accumulation and prolactin release in normal rat pituitary cells in culture. cAMP accumulation is significant (P < 0.01) at VIP concentrations as low as 1 nM and reaches a maximum with 0.1 ,IM. Addition of dexamethasone as early as 15 min before VIP inhibits VIP stimulation of both cAMP production and PRL secretion. The rapid inhibition is dose-dependent: it appears at doses as low as 0.01 pM and is complete at 1 pM dexamethasone. Increasing concentrations of dexamethasone induce a noncompetitive type of inhibition, as shown by the decrease in Vm.,. with no change in the apparent K.for VIP. Cycloheximide (1 mM) counteracts the inhibitory effect of dexamethasone on VIP-induced cAMP production, which suggests the involvement ofa rapid protein synthesis mechanism. Ru-26988, a specific glucocorticoid devoid of any mineralocorticoid activity and which does not bind to intracellular transcortin-like component, also produces an inhibition of VIP-induced cAMP accumulation. Corticosterone also inhibits VIP-induced cAMP production but at concentrations higher than those ofdexamethasone. In contrast, aldosterone, progesterone, estradiol, and testosterone have no effect. These results demonstrate that, in normal rat pituitary cells in culture, glucocorticoids at physiological concentrations rapidly inhibit the cAMP production and prolactin release induced by VIP by acting through specific glucocorticoid receptors.Vasoactive intestinal peptide (VIP) (9,10).In the light of both in vivo and in vitro experiments (6, 11), we suggested that corticosteroids could be involved in the regulation of VIP action on the adenohypophysis. We had previously shown that addition of dexamethasone (Dex) for 2 days to cultures of enriched pituitary rat lactotrophs completely abolished the stimulatory effect ofVIP on PRL secretion (6). Therefore, we have investigated (a) the involvement of the cAMP system in the biological effect of VIP on PRL release, (b) the kinetics and the stoichiometry of the interaction between VIP and corticosteroids, and (c) the mechanism by which Dex inhibits PRL release at the pituitary level.In the present communication, we present evidence that, in normal rat pituitary cells in culture, Dex at concentrations as low as 1 pM rapidly inhibits both the cAMP accumulation and the PRL release induced by VIP, by acting through specific glucocorticoid receptors. MATERIALS AND METHODSIsolation and Cell Culture. Male Wistar rats (45-60 days old) were used. Fifteen to 20 anterior pituitaries were minced in small pieces and dispersed enzymatically by incubation in 15-20 ml of minimal essential medium with Earle's salts containing 0.1% trypsin (1:250) (GIBCO) and 0.1% fatty acid-free bovine serum albumin (Sigma) for 2 hr at 370C (12) at pH 7.5 in a silicone-treated Bellco spinner flask. Cells were filtered though 100-,um-mesh nylon to remove DNA of broken cells and centrifuged at 400 g for 5 min; the pellet was resuspended, w...

show abstract

“…From these findings, VIP seems to be involved in the control of pituitary hormone secretion. Actually, several reports indicated that VIP stimulates the secretion of prolactin, affecting prolactin cells directly (SHAAR et al, 1979;ENJALBERT et al, 1980;ROTSZTEJN et al, 1980). Moreover, the release of growth hormone was shown to be influenced by VIP indirectly through the inhibition of somatostatin secretion TAPIA-ARANCIBIA et a1.,1980).…”

mentioning

confidence: 99%

Inhibitory effect of cholecystokinin octapeptide on vasoactive intestinal peptide-induced stimulation of adrenocortical secretion.

Itoh

Hirota

1983

Jpn.J.Physiol

View full text Add to dashboard Cite

show abstract

Effect of vasoactive intestinal peptide (VIP) on the release of adenohypophyseal hormones from purified cells obtained by unit gravity sedimentation

Cited by 21 publications

References 0 publications

Ultrastructural Evidence for Endogenous Vasoactive Intestinal Peptide-Like Immunoreactivity in the Pituitary Gland

Ultrastructural Evidence for Endogenous Vasoactive Intestinal Peptide-Like Immunoreactivity in the Pituitary Gland

Rapid glucocorticoid inhibition of vasoactive intestinal peptide-induced cyclic AMP accumulation and prolactin release in rat pituitary cells in culture.

Inhibitory effect of cholecystokinin octapeptide on vasoactive intestinal peptide-induced stimulation of adrenocortical secretion.

Contact Info

Product

Resources

About